Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant XELOX vs Adjuvant XELOX in Rectal Cancer
NCT00421824Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2006
- Primary completion
- Nov 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin and capecitabine in rectal cancer (2 arms), sponsored by Sanofi. Primary endpoint: Complete Pathological Response Rate. Started May 2006; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00421824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421824.